SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.

Key facts

Study ID

NCT04381468

Run by

Vaccinex Inc.

People needed

50

Starts

2021-07-22

Expected to finish

2024-06-05

Last updated by the study team

2024-08-22

Who can join

Age: 55 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Pacific Research Network, Inc — San Diego, California, United States
• Georgetown University — Washington D.C., District of Columbia, United States
• Brain Matters Research — Delray Beach, Florida, United States
• Neuropsychiatric Research Center of Southwest Florida — Fort Myers, Florida, United States
• JEM Research Institute — Lake Worth, Florida, United States
• Premiere Research Institute of Palm Beach, Neurology — Palm Beach, Florida, United States
• Brain Matters Research — Stuart, Florida, United States
• Indiana University School of Medicine — Indianapolis, Indiana, United States
• University of Kansas Medical Center — Fairway, Kansas, United States
• Neurological Associates of Albany — Albany, New York, United States
• Dent Neurological Associates — Amherst, New York, United States
• Columbia University Irving Medical Center — New York, New York, United States
• University of Rochester Medical Center — Rochester, New York, United States
• Re-Cognition Health — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.